Anti-IL-36R Monoclonal Antibody and Use Thereof for Inflammatory Disease Treatment
Summary
USPTO published patent application US20260098101A1 from QYUNS THERAPEUTICS CO., LTD. covering an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody for inflammatory disease treatment. The application was filed on December 4, 2025. The antibody comprises six complementarity determining regions with amino acid sequences specified in the filing, and the applicant claims superior neutralizing activity compared to Spesolimab at the cellular level.
What changed
USPTO published patent application US20260098101A1 disclosing an anti-human IL-36R monoclonal antibody comprising three heavy chain CDR regions (CDR-H1, CDR-H2, CDR-H3) and three light chain CDR regions (CDR-L1, CDR-L2, CDR-L3) with amino acid sequences as shown in SEQ ID NO: 1 through SEQ ID NO: 6. The application claims the antibody has comparable binding affinity to human IL-36R but superior neutralizing activity compared to Spesolimab.\n\nThis is a patent application publication, not a granted patent. Pharmaceutical companies developing biologic therapeutics targeting the IL-36 pathway should monitor this application for potential freedom-to-operate implications. Patent prosecution will determine whether the claims are ultimately allowed. The application does not create compliance obligations but may inform competitive intelligence regarding antibody-based inflammatory disease therapeutics.
What to do next
- Monitor for updates
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTI-HUMAN INTERLEUKIN 36 RECEPTOR MONOCLONAL ANTIBODY AND USE THEREOF
Application US20260098101A1 Kind: A1 Apr 09, 2026
Assignee
QYUNS THERAPEUTICS CO., LTD.
Inventors
Jiwan QIU, Wang LI, Yi ZHOU, Wei CHEN, Yong KONG, Huaiyao QIAO, Yiliang WU, Tao CHEN
Abstract
The present invention provides an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody and a use thereof. The monoclonal antibody comprises three heavy chain complementarity determining regions CDR-H1, CDR-H2 and CDR-H3 and three light chain complementarity determining regions CDR-L1, CDR-L2 and CDR-L3, and the amino acid sequences of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3 are as shown in SEQ ID NO: 1 to SEQ ID NO: 6, respectively. Compared with Spesolimab, the monoclonal antibody has comparable binding affinity to human IL-36R, and the neutralizing activity of the monoclonal antibody at the cellular level is superior to that of Spesolimab.
CPC Classifications
C07K 16/2866 C07K 2317/24 C07K 2317/76 C07K 2317/92
Filing Date
2025-12-04
Application No.
19409040
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.